Amphastar Pharmaceuticals (AMPH) Share-based Compensation (2013 - 2026)

Amphastar Pharmaceuticals' Share-based Compensation history runs 14 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 270.55% year-over-year to $31.1 million in Q1 2026; TTM through Mar 2026 was $31.1 million, a 22.44% increase from a year earlier, with the FY2025 full-year figure at $27.3 million, up 11.94% from the prior year.
• Share-based Compensation climbed to $31.1 million in Q1 2026 per AMPH's latest filing, from $6.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $31.1 million in Q1 2026 and bottomed at $4.2 million in Q2 2022.
• The 5-year median for Share-based Compensation is $5.6 million (2024), against an average of $9.3 million.
• Biggest YoY gain for Share-based Compensation was 759.8% in 2022; the steepest drop was 30.39% in 2022.
• Year by year, Share-based Compensation stood at $4.3 million in 2022, then advanced by 7.39% to $4.6 million in 2023, then advanced by 21.85% to $5.6 million in 2024, then gained by 10.17% to $6.2 million in 2025, then jumped by 401.21% to $31.1 million in 2026.
• Per Business Quant, the three latest AMPH Share-based Compensation figures stand at $31.1 million (Q1 2026), $6.2 million (Q4 2025), and $23.9 million (Q3 2025).